News

Divaka Perera, MD, at ACC.26

The second day of the American College of Cardiology’s annual conference started with a series of highly anticipated interventional cardiology trials.

 Stavros V. Konstantinides, MD, PhD, presenting data at ACC.26

New 30-day data presented at ACC.26 helped answer questions cardiologists have had been asking for years. “Thank you for bringing PE into the future," one vascular specialist said from the stage.  

voice audio recording smartphone

An advanced algorithm that looks for signs of heart failure in five-second voice recordings has received the FDA's breakthrough device designation.

Thumbnail

Decreased screening rates among different subgroups highlight the ongoing need for outreach strategies that target vulnerable populations, experts contend.

Medtronic’s MiniMed 780G automated insulin delivery system

Nearly 27,000 MiniMed 780G insulin pumps were included in a new Class II recall. By taking a few basic steps, however, patients should be able to avoid any significant risks.

William P. Shutze, MD, FACS, secretary of the Society of Vascular Surgery (SVS), a vascular surgeon with Texas Vascular Associates in Plano, Texas, and a clinical associate professor of medicine at Texas A&M College of Medicine, explained the role of vascular surgeons in peripheral artery disease (PAD) and critical limb ischemia (CLI).

Vascular surgeons perform procedures interventional cardiologists and interventional radiologists do not do—so why not make sure they are part of every heart team conversation?

Northwestern deploys new mobile stroke unit

The MSU operates 365 days a year and covers 138 square miles. Hundreds of patients have been treated through the MSU, with more than 500 receiving critical care in it 2025 alone. 

UnitedHealth Group - 2

Led by a Quebec-based faith organization, a coalition of investors is asking a court to force UnitedHealth to provide details on the social impacts of its history of mergers and acquisitions. The lawsuit comes after the plaintiffs, all company shareholders, failed to get the proposal passed through internal channels. The Securities and Exchange Commission has also opted not to intervene. 

Kestra Medical Technologies

Kestra Medical Technologies, known for its wearable heart monitors and defibrillators, intends to sell 10 million common shares priced somewhere between $14 and $16 per share. 

Recently the system was struggling to keep some of its CT departments fully staffed, causing delays in care and burdensome workloads for staff. 

Charalambos Antoniades, MD, the British Heart Foundation Chair of Cardiovascular Medicine at the University of Oxford, is a co-founder of the company Caristo, which has developed technology to image coronary inflammation on coronary computed tomography angiography (CCTA) scans to visualize a key factor of residual cardiovascular risk.

New technology now being considered by the FDA for approval can capture coronary inflammation on CCTA images and provide risk assessments. What could this mean for the future of cardiac care? We spoke to one researcher to learn more.

The new cardiac PET radiotracer flurpiridaz F-18 is posed to be a major game changer and will likely lead to increased adoption of cardiac PET.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

Around the web

The second day of the American College of Cardiology’s annual conference started with a series of highly anticipated interventional cardiology trials.